We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Orkambi

News List

UK parliamentary enquiry threatens to disclose details of Vertex, NHS negotiations over Orkambi pharmafile
November 12, 2018
The UK House of Commons' Health and Social Care Committee on Friday said that it requested documents from Vertex Pharmaceuticals, NHS England and the
Ministers write letter to Vertex over Orkambi debate pharmatimespharmatimes
July 16, 2018
Ministers from the Department of Health have written a letter asking that Vertex bring negotiations with NHS England over access to cystic fibrosis drug Orkambi “to an urgent resolution”.
Vertex’ CF therapy Orkambi cleared for younger patients pharmatimes
January 11, 2018
European regulators have expanded the scope of Vertex’ Orkambi to include children with cystic fibrosis aged six through 11 who have two copies of the F508del mutation.
Vertex Receives CHMP Positive Opinion for ORKAMBI for Children with Cystic Fibrosis americanpharmaceuticacreview
November 13, 2017
Positive CHMP opinions are recommendations for approval to the European Commission, which has the authority to approve medicines for the European Union.

Previous page 1 2 Next page